Latest Hospitality News

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Decidr AI Industries has solidified its position in the agentic AI market by completing strategic acquisitions and launching its DecidrOS platform, achieving a 60% revenue increase in the December quarter.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.